Journal Article
. 2016 Feb;1().
doi: 10.1038/npjgenmed.2015.15.

A prognostic signature based on three-genes expression in triple-negative breast tumours with residual disease

Joseph A Pinto 1 Jhajaira Araujo 1 Nadezhda K Cardenas 2 Zaida Morante 1 Franco Doimi 3 Tatiana Vidaurre 4 Justin M Balko 5 Henry L Gomez 4 
  • PMID: 29263808
  •     33 References
  •     16 citations


Residual disease after neoadjuvant chemotherapy (NAC) in triple-negative breast cancer (TNBC) is related with poor prognosis; however, the risk of recurrence after 3 years from surgery, becomes similar to other breast cancer subtypes indicating that TNBC is composed of tumours of different prognosis. To evaluate genes related to TNBC aggressiveness in the outcome of TNBC resistant to NAC, we profiled 82 samples of residual tumours whose expression for 449 genes was quantified with NanoString. The validation set (GSE25066) consisted of 113 TNBC cases with residual disease. The stepwise multivariate survival analysis performed by the Cox proportional hazards mode selected CCL5, DDIT4 and POLR1C as independent prognostic factors for distant recurrence-free survival (DRFS). We developed a three-genes signature using the regression coefficients for each gene (-0.393×CCL5+0.443×DDIT4+0.490×POLR1C). The median score in the discovery set (0.1494) identified two subgroups with different DRFS (P<0.001). The median score in the validation set was 0.0024 and was able to discriminate patients with different DRFS (P=0.002). In addition, the three-genes signature was a prognostic factor in TNBC patients regardless their response to NAC (data set GSE58812; P=0.001) and in patients with oestrogen-receptor-negative tumours (data set GSE16446; P=0.041). Here we describe a prognostic signature based on expression levels of CCL5, DDIT4 and POLR1C. The knowledge about the involvement of these genes in chemotherapy resistance could improve the therapeutic strategies in TNBC.

An overview of recent developments in genomics and associated statistical methods.
Peter J Bickel, James B Brown, Haiyan Huang, Qunhua Li.
Philos Trans A Math Phys Eng Sci, 2009 Oct 07; 367(1906). PMID: 19805447
Direct multiplexed measurement of gene expression with color-coded probe pairs.
Gary K Geiss, Roger E Bumgarner, +18 authors, Krassen Dimitrov.
Nat Biotechnol, 2008 Feb 19; 26(3). PMID: 18278033
Highly Cited.
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.
Brian D Lehmann, Joshua A Bauer, +4 authors, Jennifer A Pietenpol.
J Clin Invest, 2011 Jun 03; 121(7). PMID: 21633166    Free PMC article.
Highly Cited.
A new posttranslational regulation of REDD1/DDIT4 through cleavage by caspase 3 modifies its cellular function.
A Puissant, N Fenouille, +5 authors, P Auberger.
Cell Death Dis, 2014 Jul 25; 5. PMID: 25058423    Free PMC article.
A review of feature selection techniques in bioinformatics.
Yvan Saeys, Iñaki Inza, Pedro Larrañaga.
Bioinformatics, 2007 Aug 28; 23(19). PMID: 17720704
Highly Cited. Review.
Supervised risk predictor of breast cancer based on intrinsic subtypes.
Joel S Parker, Michael Mullins, +17 authors, Philip S Bernard.
J Clin Oncol, 2009 Feb 11; 27(8). PMID: 19204204    Free PMC article.
Highly Cited.
Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer.
Marc Buyse, Sherene Loi, +18 authors, TRANSBIG Consortium.
J Natl Cancer Inst, 2006 Sep 07; 98(17). PMID: 16954471
Highly Cited.
Public availability of published research data in high-impact journals.
Alawi A Alsheikh-Ali, Waqas Qureshi, Mouaz H Al-Mallah, John P A Ioannidis.
PLoS One, 2011 Sep 15; 6(9). PMID: 21915316    Free PMC article.
Highly Cited.
Cloning and characterization of the human RNA polymerase I subunit hRPA40.
R Dammann, G P Pfeifer.
Biochim Biophys Acta, 1998 Apr 16; 1396(2). PMID: 9540830
Tumor-derived chemokine CCL5 enhances TGF-β-mediated killing of CD8(+) T cells in colon cancer by T-regulatory cells.
Li-Yuan Chang, Yung-Chang Lin, +11 authors, Chun-Yen Lin.
Cancer Res, 2012 Jan 28; 72(5). PMID: 22282655
On the synthesis and interpretation of consistent but weak gene-disease associations in the era of genome-wide association studies.
Muin J Khoury, Julian Little, Marta Gwinn, John P A Ioannidis.
Int J Epidemiol, 2006 Dec 22; 36(2). PMID: 17182636
Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes.
Hiroko Masuda, Keith A Baggerly, +9 authors, Naoto T Ueno.
Clin Cancer Res, 2013 Aug 21; 19(19). PMID: 23948975    Free PMC article.
Highly Cited.
Identification of genes with a correlation between copy number and expression in gastric cancer.
Lei Cheng, Ping Wang, +6 authors, Qinghua Zhang.
BMC Med Genomics, 2012 May 09; 5. PMID: 22559327    Free PMC article.
Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44).
B Gerber, S Loibl, +18 authors, German Breast Group Investigators.
Ann Oncol, 2013 Oct 19; 24(12). PMID: 24136883
Triple-negative breast cancer in Hispanic patients: high prevalence, poor prognosis, and association with menopausal status, body mass index, and parity.
Fernando Lara-Medina, Víctor Pérez-Sánchez, +9 authors, Óscar Arrieta.
Cancer, 2011 Mar 10; 117(16). PMID: 21387260
Treacher Collins Syndrome: the genetics of a craniofacial disease.
Sameep Kadakia, Samuel N Helman, +2 authors, Yadranko Ducic.
Int J Pediatr Otorhinolaryngol, 2014 Apr 03; 78(6). PMID: 24690222
The inflammatory chemokines CCL2 and CCL5 in breast cancer.
Gali Soria, Adit Ben-Baruch.
Cancer Lett, 2008 Apr 29; 267(2). PMID: 18439751
Highly Cited. Review.
PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers.
Roy R L Bastien, Álvaro Rodríguez-Lescure, +29 authors, Miguel Martín.
BMC Med Genomics, 2012 Oct 06; 5. PMID: 23035882    Free PMC article.
Highly Cited.
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.
Cornelia Liedtke, Chafika Mazouni, +10 authors, Lajos Pusztai.
J Clin Oncol, 2008 Feb 06; 26(8). PMID: 18250347
Highly Cited.
Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance.
Justin M Balko, Rebecca S Cook, +15 authors, Carlos L Arteaga.
Nat Med, 2012 Jun 12; 18(7). PMID: 22683778    Free PMC article.
Highly Cited.
RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors.
Sherene Loi, Sathana Dushyanthen, +22 authors, Justin M Balko.
Clin Cancer Res, 2015 Oct 31; 22(6). PMID: 26515496    Free PMC article.
Highly Cited.
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
Soonmyung Paik, Gong Tang, +11 authors, Norman Wolmark.
J Clin Oncol, 2006 May 25; 24(23). PMID: 16720680
Highly Cited.
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
Soonmyung Paik, Steven Shak, +12 authors, Norman Wolmark.
N Engl J Med, 2004 Dec 14; 351(27). PMID: 15591335
Highly Cited.
(V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway.
Christine A Pratilas, Barry S Taylor, +4 authors, Neal Rosen.
Proc Natl Acad Sci U S A, 2009 Mar 03; 106(11). PMID: 19251651    Free PMC article.
Highly Cited.
Predicting response and survival in chemotherapy-treated triple-negative breast cancer.
A Prat, A Lluch, +35 authors, E Alba.
Br J Cancer, 2014 Aug 08; 111(8). PMID: 25101563    Free PMC article.
mTORC1 dependent regulation of REDD1 protein stability.
Chia Yee Tan, Thilo Hagen.
PLoS One, 2013 May 30; 8(5). PMID: 23717519    Free PMC article.
Molecular stratification of triple-negative breast cancers.
Charles M Perou.
Oncologist, 2010 Dec 16; 15 Suppl 5. PMID: 21138954
Triple-negative breast cancer: clinical features and patterns of recurrence.
Rebecca Dent, Maureen Trudeau, +7 authors, Steven A Narod.
Clin Cancer Res, 2007 Aug 03; 13(15 Pt 1). PMID: 17671126
Highly Cited.
Breast cancer classification according to immunohistochemistry markers: subtypes and association with clinicopathologic variables in a peruvian hospital database.
Carlos S Vallejos, Henry L Gómez, +8 authors, Carlos E Vigil.
Clin Breast Cancer, 2010 Aug 14; 10(4). PMID: 20705562
Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.
Lisa A Carey, Charles M Perou, +14 authors, Robert C Millikan.
JAMA, 2006 Jun 08; 295(21). PMID: 16757721
Highly Cited.
An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients.
Balazs Györffy, Andras Lanczky, +4 authors, Zoltan Szallasi.
Breast Cancer Res Treat, 2009 Dec 19; 123(3). PMID: 20020197
Highly Cited.
TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer.
Neil E Bhola, Justin M Balko, +6 authors, Carlos L Arteaga.
J Clin Invest, 2013 Feb 09; 123(3). PMID: 23391723    Free PMC article.
Highly Cited.
Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets.
Justin M Balko, Jennifer M Giltnane, +24 authors, Carlos L Arteaga.
Cancer Discov, 2013 Dec 21; 4(2). PMID: 24356096    Free PMC article.
Highly Cited.
Effect of CCL5 expression in the recruitment of immune cells in triple negative breast cancer.
Jhajaira M Araujo, Andrea C Gomez, +9 authors, Joseph A Pinto.
Sci Rep, 2018 Mar 22; 8(1). PMID: 29559701    Free PMC article.
DNA Damage Inducible Transcript 4 Gene: The Switch of the Metabolism as Potential Target in Cancer.
Indira Tirado-Hurtado, Williams Fajardo, Joseph A Pinto.
Front Oncol, 2018 May 01; 8. PMID: 29707520    Free PMC article.
CAD/POLD2 gene expression is associated with poor overall survival and chemoresistance in bladder urothelial carcinoma.
Kevin B Givechian, Chad Garner, +2 authors, Patrick Soon-Shiong.
Oncotarget, 2018 Jul 25; 9(51). PMID: 30038717    Free PMC article.
A prognostic 10-lncRNA expression signature for predicting the risk of tumour recurrence in breast cancer patients.
Jianing Tang, Jiangbo Ren, +6 authors, Gaosong Wu.
J Cell Mol Med, 2019 Aug 21; 23(10). PMID: 31429520    Free PMC article.
Genetic Variation in CCL5 Signaling Genes and Triple Negative Breast Cancer: Susceptibility and Prognosis Implications.
Jingxuan Shan, Aziz Chouchane, +11 authors, Lotfi Chouchane.
Front Oncol, 2020 Jan 11; 9. PMID: 31921621    Free PMC article.
Prognostic nomogram of hypoxia-related genes predicting overall survival of colorectal cancer-Analysis of TCGA database.
Joon-Hyop Lee, Sohee Jung, +7 authors, Young Jun Chai.
Sci Rep, 2019 Feb 14; 9(1). PMID: 30755640    Free PMC article.
Depletion of the Transcriptional Coactivator Amplified in Breast Cancer 1 (AIB1) Uncovers Functionally Distinct Subpopulations in Triple-Negative Breast Cancer.
F R Saenz, V Ory, +5 authors, A T Riegel.
Neoplasia, 2019 Aug 23; 21(10). PMID: 31437536    Free PMC article.
An estrogen receptor (ER)-related signature in predicting prognosis of ER-positive breast cancer following endocrine treatment.
Jianing Tang, Qiuxia Cui, +3 authors, Gaosong Wu.
J Cell Mol Med, 2019 May 28; 23(8). PMID: 31124293    Free PMC article.
Peripheral blood transcriptome identifies high-risk benign and malignant breast lesions.
Hong Hou, Yali Lyu, +5 authors, Changming Cheng.
PLoS One, 2020 Jun 05; 15(6). PMID: 32497068    Free PMC article.
Resistance to Neoadjuvant Treatment in Breast Cancer: Clinicopathological and Molecular Predictors.
María Rosario Chica-Parrado, Ana Godoy-Ortiz, +3 authors, Emilio Alba.
Cancers (Basel), 2020 Jul 28; 12(8). PMID: 32708049    Free PMC article.
Precision medicine for locally advanced breast cancer: frontiers and challenges in Latin America.
Joseph A Pinto, César H Saravia, +10 authors, Henry L Gómez.
Ecancermedicalscience, 2019 Feb 23; 13. PMID: 30792813    Free PMC article.
Post-neoadjuvant treatment and the management of residual disease in breast cancer: state of the art and perspectives.
Rafael Caparica, Matteo Lambertini, +3 authors, Martine Piccart.
Ther Adv Med Oncol, 2019 Mar 06; 11. PMID: 30833989    Free PMC article.
Decoding Immune Heterogeneity of Triple Negative Breast Cancer and Its Association with Systemic Inflammation.
Sandra Romero-Cordoba, Elisabetta Meneghini, +6 authors, Francesca Bianchi.
Cancers (Basel), 2019 Jul 03; 11(7). PMID: 31261762    Free PMC article.
Identification of oncolytic vaccinia restriction factors in canine high-grade mammary tumor cells using single-cell transcriptomics.
Béatrice Cambien, Kevin Lebrigand, +16 authors, Georges Vassaux.
PLoS Pathog, 2020 Oct 20; 16(10). PMID: 33075093    Free PMC article.
In silico evaluation of DNA Damage Inducible Transcript 4 gene (DDIT4) as prognostic biomarker in several malignancies.
Joseph A Pinto, Christian Rolfo, +11 authors, Henry L Gomez.
Sci Rep, 2017 May 10; 7(1). PMID: 28484222    Free PMC article.
siRNA Knockdown of REDD1 Facilitates Aspirin-Mediated Dephosphorylation of mTORC1 Target 4E-BP1 in MDA-MB-468 Human Breast Cancer Cell Line.
Aistė Savukaitytė, Greta Gudoitytė, +2 authors, Elona Juozaitytė.
Cancer Manag Res, 2021 Feb 13; 13. PMID: 33574709    Free PMC article.